How to Identify Drug-Related Problems (DRPs): A Pharmacist's Guide

Identifying drug-related problems is one of the most clinically valuable things a pharmacist does. It is the skill that distinguishes a pharmacist functioning as a clinical practitioner from one functioning purely as a dispenser. Every comprehensive medication review, care plan encounter, prescription renewal assessment, and minor ailment consultation requires systematic DRP identification — and doing it well is what generates meaningful clinical value for patients and referring prescribers.

This guide walks through the full DRP identification process: what a DRP is, all 14 categories with illustrative triggers, a step-by-step review method, worked illustrative examples, and how to write, prioritize, and document DRP statements effectively. Confirm all clinical content against current guidelines and individual patient factors.

What Is a Drug-Related Problem?

A drug-related problem (DRP) is any undesirable event or risk experienced by a patient that involves, or is suspected to involve, drug therapy — and that actually or potentially interferes with a desired patient outcome. The term covers a broad spectrum: a medication that is no longer needed, a condition that is inadequately treated, a dose that is too high or too low, an adverse effect the patient is experiencing, a monitoring gap, an adherence barrier, or a clinically significant drug interaction.

The systematic concept underlying DRP identification is straightforward: every medication a patient takes should have a valid indication, be the most appropriate option, be dosed correctly, be tolerated, be monitored appropriately, and actually be taken as intended. Any deviation from this ideal — whether real or at risk of occurring — is a potential DRP. A structured framework turns this concept into a reliable clinical checklist.

The 14 DRP Categories

The 14-category DRP framework used in Canadian pharmacy practice gives clinicians a comprehensive lens to evaluate medication therapy. Each category represents a distinct type of drug-related problem with its own set of clinical triggers and documentation requirements. Use this list as a systematic checklist — working through each category for every patient rather than relying on pattern recognition alone.

1. Unnecessary drug therapy — The patient is taking a medication for which there is no valid, current medical indication. Illustrative trigger: a medication started for a short-term indication that has since resolved, with no reassessment or deprescribing discussion documented. Confirm current indication against the patient's active problem list.
2. Needs additional drug therapy — The patient has a medical condition that warrants pharmacotherapy, but no treatment has been initiated. Illustrative trigger: a documented diagnosis without any corresponding medication or non-pharmacological plan in the chart, or a condition identified during review that has not been addressed therapeutically. Confirm against current guideline recommendations for the specific condition.
3. Ineffective drug — The medication being used is not the most effective option for the patient's condition, based on current evidence or clinical guidelines. Illustrative trigger: use of a second- or third-line agent when first-line options have not been tried or are not contraindicated, or documented treatment failure without therapeutic substitution. Confirm that alternative options are appropriate for this patient per current guidelines.
4. Dosage too low — The prescribed dose is below the therapeutic range needed to produce the desired clinical effect. Illustrative trigger: a condition remaining uncontrolled (for example, blood pressure, blood glucose, or LDL above target) despite a dose that is lower than current guideline recommendations for this patient profile. Confirm therapeutic targets per current Canadian guidelines and individualize to the patient.
5. Dosage too high — The prescribed dose exceeds what is needed or what is safe for this patient. Illustrative trigger: a standard dose in a patient whose renal or hepatic function requires dose reduction, or a dose that is producing toxicity signs without therapeutic benefit. Confirm dose adjustment requirements against current renal/hepatic dosing references.
6. Adverse drug reaction (ADR) — The patient is experiencing a harmful or unintended effect from a medication at a dose normally used for treatment. Illustrative trigger: a new symptom appearing shortly after a medication was started or its dose was increased, or a known ADR profile symptom in a patient on a medication with that risk. Assess causality using standard methods (e.g., Naranjo scale as a prompt for documentation) and confirm against current ADR references.
7. Drug interaction — A clinically significant pharmacokinetic or pharmacodynamic interaction exists between two or more medications, supplements, or substances in the patient's regimen. Illustrative trigger: a newly added medication that affects the metabolism or effect of an established drug, or a combination known to produce additive toxicity. Assess clinical significance, not just theoretical interaction flags — confirm against current drug interaction resources.
8. Non-adherence — The patient is not taking the medication as prescribed, whether due to cost, complexity, side effects, beliefs, practical barriers, or lack of understanding. Illustrative trigger: frequent early refills or late refills, a patient's own report of missed doses, or clinical data (e.g., uncontrolled disease) inconsistent with the expected effect of the prescribed therapy. Address root cause, not just the gap.
9. Needs monitoring — Required laboratory or clinical monitoring for a medication or condition is overdue or has never been performed. Illustrative trigger: a medication requiring regular renal function, electrolyte, or organ function monitoring without a recent result on file. Confirm current monitoring frequency recommendations for the specific medication and indication.
10. Suboptimal therapy — The current medication is working but a safer, better-tolerated, or more evidence-based alternative exists for this patient. Illustrative trigger: a patient tolerating a medication that carries unnecessary risk compared to a guideline-preferred option with equivalent efficacy. Consider patient preference and clinical context before recommending a switch.
11. Contraindicated medication — The patient is taking a drug that is contraindicated given their medical history, concurrent conditions, or other medications. Illustrative trigger: a medication prescribed before a new diagnosis was established, or a drug class flagged as contraindicated in the patient's clinical profile. Confirm contraindication against current product monograph and guideline sources.
12. Duplicate therapy — The patient is taking two or more medications from the same pharmacological class without a documented clinical rationale for combination. Illustrative trigger: two agents with the same mechanism of action appearing on the medication list, or two prescriptions from different prescribers addressing the same indication. Confirm that the duplication is not intentional before flagging.
13. Drug without indication — A medication is being continued past its intended duration or its original indication is no longer present in the patient's active problem list. Illustrative trigger: a medication initiated for a time-limited condition (such as a short-term infection or acute symptom) that is still being dispensed months or years later with no ongoing indication documented. Initiate a deprescribing discussion per current deprescribing guidelines.
14. Untreated condition — A diagnosed condition is present in the patient's record without any corresponding treatment — pharmacological or non-pharmacological. Illustrative trigger: a condition listed in the problem list that has no medications, referrals, or documented management plan attached to it. Differentiate from a condition that is being intentionally monitored without treatment — the latter requires documentation of the watchful waiting rationale.

A Systematic Approach to DRP Identification

Reviewing medications in isolation is the most common way to miss DRPs. A systematic approach cross-references three data sources — the patient's condition list, the medication list, and objective clinical data — in a structured sequence. Use this four-step method as your standard operating procedure for any comprehensive medication review.

Step 1: Review Each Condition Against Its Treatment

Start with the patient's active problem list. For each condition, ask: Is there a medication or non-pharmacological treatment for it? Is the treatment current-guideline appropriate? Is the condition controlled based on objective data? An uncontrolled condition is a DRP signal — it may indicate dosage too low, ineffective drug, non-adherence, or a drug interaction reducing efficacy. Confirm therapeutic targets per current Canadian guidelines for each condition and individualize to the patient's context.

Step 2: Review Each Medication Against Its Indication

For each medication on the list, ask: What condition is this treating? Is that condition still active? Is this the most appropriate agent per current guidelines? Has the indication changed since this medication was started? Medications that cannot be matched to a current indication are candidates for the unnecessary drug therapy, drug without indication, or duplicate therapy categories. Be thorough — polypharmacy lists commonly include medications started years earlier whose rationale has been lost.

Step 3: Review the Full Medication List for Interactions and Duplication

Review the complete medication list — including over-the-counter drugs, supplements, and products from multiple prescribers — for clinically significant interactions and therapeutic duplication. Focus on combinations with known serious consequences (for example, additive bleeding risk, QT prolongation, serotonin syndrome risk, or major CYP-mediated interactions). Use a systematic interaction checker as a prompt, then apply clinical judgment to assess true significance for this patient. Confirm against current drug interaction resources.

Step 4: Assess Adherence and Monitoring Gaps

Review dispensing history and patient-reported adherence for each medication. Ask about cost, complexity, side effects, and understanding. Compare recent lab results and clinical measurements against the monitoring requirements for each drug and condition. Flag overdue monitoring. Adherence and monitoring DRPs are often underidentified because they require asking beyond the prescription — make them a routine part of every review.

Worked Examples: Brief Snapshots Across DRP Categories

Unnecessary drug therapy: A patient's medication list includes a proton pump inhibitor started during a hospitalization three years ago. The original indication (stress ulcer prophylaxis) is not present in the community setting. No ongoing indication is documented. Potential DRP: unnecessary drug therapy. Consider discussing with the prescriber re: deprescribing per current deprescribing guidance, confirm against individual patient factors.

Needs additional therapy: A patient with a documented diagnosis of a chronic condition has no corresponding pharmacotherapy on their medication list and no documentation of a watchful waiting decision. Potential DRP: needs additional drug therapy. Consider discussing with the prescriber whether treatment initiation is appropriate per current guidelines for this patient.

Dose too low: A patient on a first-line antihypertensive for several months has repeated blood pressure readings above their individualized target. The current dose is at the lower end of the guideline range and has not been titrated. Potential DRP: dosage too low. Consider discussing with the prescriber re: dose titration, per current guideline targets and patient tolerability — confirm targets against current Canadian hypertension guidelines.

Adverse drug reaction: A patient recently started on a medication known to cause a common class-effect side effect reports a new symptom consistent with that side effect. Potential DRP: adverse drug reaction. Document the temporal relationship, assess causality, and consider discussing with the prescriber re: dose reduction, alternative agent, or management of the side effect — confirm against current references.

Drug interaction: A patient on a stable oral anticoagulant has a newly added antibiotic known to affect anticoagulant metabolism. Potential DRP: drug interaction with risk of altered anticoagulant effect. Consider discussing with the prescriber re: monitoring plan and whether the combination requires any therapeutic adjustment — confirm clinical significance against current interaction resources for this specific patient.

Non-adherence: A patient's dispensing history shows consistently late refills for a key chronic disease medication, and their condition remains poorly controlled. The patient reports they sometimes skip doses because of side effects. Potential DRP: non-adherence due to tolerability barriers. Address the underlying cause — consider discussing side effect management, alternative agents, or adherence supports with the prescriber, per current guidelines.

Writing Strong DRP Statements

A DRP statement is only as useful as the information it contains. A vague DRP entry ("blood pressure high") provides little value. A well-constructed DRP statement gives the next clinician — and the prescriber — everything they need to act. Strong DRP statements contain four elements:

1. The problem: What is the clinical issue? State it specifically (e.g., "blood pressure persistently above individualized target per recent readings").
2. The DRP category: Name the category explicitly (e.g., "dosage too low") so the documentation is structured and searchable.
3. The patient-specific evidence: Cite the objective data that supports the DRP identification (e.g., "three consecutive readings above target over the past two months; current dose is at the lower end of the guideline range and has not been titrated").
4. The recommendation: State a clear, actionable next step framed as a discussion or consideration rather than a directive (e.g., "consider discussing dose titration with the prescriber per current Canadian guideline targets, individualized to patient tolerability"). Always confirm against current guidelines and patient-specific factors.

Avoid vague recommendations like "optimize therapy" or "consider adjustment." Be specific about what you are suggesting, why, and to whom you are communicating it.

Prioritizing DRPs

When a medication review uncovers multiple DRPs, prioritization ensures that the most clinically urgent problems receive immediate attention. Use two axes: severity (how harmful is this DRP if left unresolved?) and urgency (how quickly does this need to be acted on?).

Safety-critical DRPs — contraindicated medications, serious drug interactions, active adverse drug reactions, or severely supratherapeutic doses — should be addressed first, typically with direct prescriber contact. Efficacy DRPs — conditions that are inadequately treated, doses that are below target, or monitoring that is overdue — are important but can generally follow in priority. Preventive or optimization DRPs — suboptimal therapy where a safer alternative exists, or a theoretical monitoring gap without current consequences — can be queued for the next appropriate clinical encounter.

Document your prioritization rationale. It demonstrates clinical reasoning and helps the prescriber understand why some DRPs are flagged as requiring immediate follow-up while others are noted for routine discussion.

Documenting DRPs Properly

Each identified DRP should be documented with enough detail for another clinician to understand the problem, the evidence, and the recommended action without needing to reconstruct your reasoning. At minimum, document:

• The DRP category
• The medication(s) and/or condition(s) involved
• The clinical evidence supporting the identification (lab values, symptom descriptions, dispensing history, guideline reference as applicable)
• The recommended intervention, framed as a discussion or consideration
• The expected outcome and the monitoring or follow-up plan
• Prescriber communication — whether a fax, direct contact, or referral to the care plan report — and the date

For structured care plan documentation, DRP statements are typically organized by condition and cross-referenced to the goals of therapy and monitoring plan. This format makes it easy for prescribers to see the clinical rationale and respond. For more on care plan documentation structure, see our pharmacist care plans guide.

Common DRP Identification Mistakes to Avoid

• Reviewing medications without the condition list: Medications reviewed in isolation cannot reveal untreated conditions or unnecessary therapy. Always start with the problem list.
• Accepting "no DRPs found" without a documented review: If your note says no DRPs were identified, it should also describe what was reviewed and how the conclusion was reached.
• Conflating potential DRPs with confirmed DRPs: A drug interaction flag from a software tool is a prompt for clinical assessment — it is not a confirmed DRP until you apply clinical judgment and determine it is significant for this patient.
• Skipping adherence and monitoring categories: These categories are systematically underidentified because they require active inquiry rather than chart review alone. Build them into every review.
• Writing DRP statements without a recommendation: A documented problem without a recommended action is an incomplete clinical note. Every DRP statement should end with a concrete next step.
• Applying the same therapeutic target to every patient: Guideline targets are population-based starting points. Individual patient factors — age, comorbidities, functional status, patient preferences — require you to individualize targets and recommendations. Confirm with current guidelines.

Tools That Streamline DRP Identification

Structured clinical decision support tools can significantly reduce the cognitive burden of DRP identification by systematically flagging potential problems across all 14 categories. Rather than relying on memory or pattern recognition, a well-designed tool prompts the pharmacist to consider each DRP category for the specific patient profile — conditions, medications, lab values, age, renal function — and surfaces relevant signals for pharmacist assessment.

RPhNote's Care Plan module includes a DRP identification engine that cross-references patient data against all 14 DRP categories and generates suggested DRP flags for pharmacist review. The pharmacist selects which DRPs are clinically relevant, adds patient-specific evidence, and documents the intervention plan — combining the efficiency of systematic screening with professional clinical judgment. All generated outputs require pharmacist review and remain the pharmacist's professional responsibility before being entered into the clinical record or communicated to a prescriber.

To learn more about how DRPs fit into the broader documentation workflow, see our guide to pharmacist care plans and our article on documenting minor ailment prescribing in Canada.

Frequently Asked Questions

What is the difference between a DRP and a medication error?

A drug-related problem is any undesirable event or risk involving drug therapy that actually or potentially interferes with a desired patient outcome — it includes both errors and non-error situations such as undertreated conditions, adverse reactions, or non-adherence. A medication error is a preventable event caused by inappropriate medication use. All medication errors are DRPs, but not all DRPs are medication errors. DRP identification in clinical practice is broader and more patient-centred than error detection alone.

How many DRPs should I identify in a care plan review?

There is no set number. A thorough review should identify all clinically significant DRPs present for a specific patient. Quality and completeness matter more than quantity — a well-documented DRP with clear reasoning and an actionable recommendation is far more valuable than a long list of vague or low-priority observations.

What if a medication appears appropriate but the condition is still uncontrolled?

Uncontrolled conditions despite seemingly appropriate therapy are one of the most important DRP signals. The underlying cause could be dosage too low, non-adherence, an unrecognized drug interaction reducing efficacy, or the medication simply not being effective for this patient. Use objective data to document the gap, then work through the possible causes systematically. Consider discussing findings with the prescriber, per current guidelines and individual patient factors.

How do I prioritize DRPs when I identify several at once?

Prioritize by clinical urgency first: a safety-critical DRP (contraindicated drug, serious drug interaction, active adverse effect) takes precedence. Within the same urgency tier, consider impact on patient outcomes and patient-expressed priorities. Document your prioritization rationale so your clinical reasoning is transparent in the record.

Can software tools identify DRPs automatically?

Structured decision support tools can screen for potential DRPs by cross-referencing patient data against known triggers. However, software cannot replace pharmacist clinical judgment. Automated flags are prompts for pharmacist review, not conclusions. The pharmacist must assess each flag in context, apply current guideline knowledge, and determine whether a true DRP exists. All outputs require pharmacist review before entering the clinical record.

Key Takeaways

• Use all 14 DRP categories as a systematic checklist for every medication review — pattern recognition alone will miss problems
• Cross-reference the condition list and the medication list in both directions: every condition should have a treatment, every medication should have an indication
• Review the full medication list for interactions and duplication; assess adherence and monitoring gaps actively, not just by chart review
• Write DRP statements with four elements: the problem, the category, the patient-specific evidence, and a concrete recommendation framed as a discussion or consideration
• Prioritize DRPs by severity and urgency; document your prioritization rationale
• Clinical decision support tools can augment systematic DRP screening, but all outputs require pharmacist review and professional judgment before use
• Confirm all therapeutic targets and recommendations against current Canadian guidelines and individual patient factors